NCT03573648 2026-03-19
ImmunoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04004442 2026-03-13
COAXIN
University of Oklahoma
Phase 1 Active not recruiting
NCT07460245 2026-03-10
AVESEC
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT03719768 2026-03-02
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03006848 2026-02-23
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT03252938 2026-02-19
INSIGHT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1 Active not recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT03944941 2026-02-05
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT04701918 2026-01-22
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT04360941 2026-01-21
PAveMenT
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05327686 2026-01-14
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07110038 2026-01-12
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06518564 2026-01-07
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting